The global Cerebroprotein Hydrolysate for Injection(Ⅲ) market size is predicted to grow from US$ 451 million in 2024 to US$ 828 million in 2030; it is expected to grow at a CAGR of 10.6% from 2024 to 2030.
Cerebroprotein Hydrolysate for Injection（Ⅲ) is a peptide neurotrophic drug unique to the brain. It can act on the central nervous system in various ways, regulate and improve neuronal metabolism, promote synapse formation, induce neuronal differentiation, and further protect nerve cells from various ischemic and neurotoxin damage. The drug can pass through the blood-brain barrier, promote protein synthesis in the brain, affect the respiratory chain, have anti-hypoxia protection ability, and improve brain energy metabolism. It activates adenylate cyclase and catalyzes other hormone systems. It provides neurotransmitters, peptide hormones and coenzyme precursors.
The Cerebroprotein Hydrolysate drug market is experiencing growth, driven by the rising prevalence of neurological disorders such as Alzheimer's disease, Parkinson's disease, and traumatic brain injuries, particularly among aging populations. These drugs, derived from animal brain proteins, are used to support neuroprotection, enhance cognitive function, and promote recovery in patients with various central nervous system (CNS) conditions. Increased awareness of neurological health and the growing demand for effective neuroprotective therapies are major factors contributing to market expansion. Emerging markets in Asia-Pacific are seeing rapid adoption due to improving healthcare infrastructure and increasing incidences of neurological diseases. However, the market faces challenges such as regulatory scrutiny over the use of animal-derived products, potential adverse effects, and competition from alternative neurotherapeutic agents. Continuous research and development, along with advancements in biotechnology, are expected to shape the market's future trajectory.
Segmentation by Type:
- 30mg/Bottle (Calculated by Total Nitrogen)
- 60mg/Bottle (Calculated by Total Nitrogen)
Segmentation by Application:
- Hospital Pharmacy
- Retail Pharmacy
- Others
This report also splits the market by region:
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Companys Coverage:
- Sihuan Pharm
- Shanxi Pude Pharma
- Harbin Medisan Pharmaceutical
- Hainan Unipul Pharmaceutical
- ApicHope Pharmaceutical
- Tianda Pharmaceuticals
Key Questions Addressed in this Report
- What is the 10-year outlook for the global Cerebroprotein Hydrolysate for Injection(Ⅲ) market?
- What factors are driving Cerebroprotein Hydrolysate for Injection(Ⅲ) market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Cerebroprotein Hydrolysate for Injection(Ⅲ) market opportunities vary by end market size?
- How does Cerebroprotein Hydrolysate for Injection(Ⅲ) break out by Type, by Application?
Frequently Asked Questions
What is the USP of the report? expand_more
What are the key content of the report? expand_more
- Global Market Players
- Geopolitical regions
- Consumer Insights
- Technological advancement
- Historic and Future Analysis of the Market